Breakthrough status for Pfizer/Spark haemophilia gene therapy
Pfizer and Spark Therapeutics say their investigational haemophilia B drug SPK-9001 has been awarded breakthrough therapy status by the US Food and Drug Administration.
Read More
Tag: SPK-9001
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
